Artal Group S.A. increased its position in shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) by 66.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 500,000 shares of the biotechnology company’s stock after purchasing an additional 200,000 shares during the quarter. Artal Group S.A. owned approximately 0.71% of Adaptimmune Therapeutics PLC worth $4,095,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. KCG Holdings Inc. purchased a new position in Adaptimmune Therapeutics PLC during the first quarter worth about $133,000. Dynamic Technology Lab Private Ltd purchased a new position in Adaptimmune Therapeutics PLC during the third quarter worth about $199,000. Paloma Partners Management Co purchased a new position in Adaptimmune Therapeutics PLC during the first quarter worth about $165,000. OxFORD Asset Management LLP purchased a new position in Adaptimmune Therapeutics PLC during the second quarter worth about $156,000. Finally, Virtu KCG Holdings LLC boosted its holdings in Adaptimmune Therapeutics PLC by 108.0% during the second quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 26,105 shares during the last quarter. Institutional investors and hedge funds own 67.93% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/11/20/artal-group-s-a-has-4-10-million-position-in-adaptimmune-therapeutics-plc-adap.html.
Several research analysts recently weighed in on ADAP shares. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Leerink Swann restated an “outperform” rating and set a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a report on Wednesday, October 4th. SunTrust Banks, Inc. restated a “buy” rating and set a $10.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Thursday, October 12th. Finally, TheStreet upgraded shares of Adaptimmune Therapeutics PLC from a “d” rating to a “c” rating in a report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $11.58.
Adaptimmune Therapeutics PLC (ADAP) traded down $0.14 on Monday, reaching $7.88. 129,600 shares of the company’s stock were exchanged, compared to its average volume of 258,525. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $9.29.
Adaptimmune Therapeutics PLC Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC (NASDAQ:ADAP).
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.